The angiopoietin: TIe 2 interaction: A potential target for future therapies in human vascular disease

Cytokine and Growth Factor Reviews

Volumn 24, Issue 6, 2013, Pages 579-592

  Moss, Andrew ^a  

^a JAMES PAGET UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Angiopoietin; Inflammatory; Therapy; Tie2

Indexed keywords

ADENOVIRUS VECTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN 2 ANTIBODY; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; COMP ANGIOPOIETIN 1; COMPANG1; CVX 060; GELATINASE B; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; MONOCLONAL ANTIBODY; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; RECOMBINANT ANGIOPOIETIN 1; RECOMBINANT ANGIOPOIETIN DERIVATIVE; RECOMBINANT PROTEIN; SCATTER FACTOR; SUNITINIB; TISSUE PLASMINOGEN ACTIVATOR; TREBANANIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN A;

ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BLOOD VESSEL PERMEABILITY; BRAIN ISCHEMIA; BREAST CARCINOMA; CANCER RECURRENCE; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG MECHANISM; ENDOTHELIUM CELL; GENE THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; LEUKOCYTE MIGRATION; LIMB ISCHEMIA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY CARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TARGETING; PROTEINURIA; RECEPTOR BINDING; REVIEW; RHEUMATIC DISEASE; SEPSIS; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT RESPONSE; TUMOR VASCULARIZATION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULITIS; VIRAL GENE DELIVERY SYSTEM; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS; ANGIOPOIETIN; INFLAMMATORY; THERAPY; TIE2;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; HUMANS; RECEPTOR, TIE-2; VASCULAR DISEASES;

EID: 84888301087     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2013.05.009     Document Type: Review

References (198)

1. Davis S., Aldrich T.H., Jones P.F., Acheson A., Compton D.L., Jain V., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996, 87:1161-1169.
2. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277(5322):55-60.
3. Yuan H.T., Khankin E.V., Karumanchi S.A., Parikh S.M. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Molecular and Cellular Biology 2009, 29:2011-2022.
4. Kämpfer H., Pfeilschifter J., Frank S. Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: a comparative study of normal and impaired repair. Laboratory Investigation 2001, 81:361-373.
5. Barton W.A., Tzvetkova-Robev D., Miranda E.P., Kolev M.V., Rajashankar K.R., Himanen J.P., et al. Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex. Nature Structural and Molecular Biology 2006, 13:524-532.
6. Kim K.T., Choi H.H., Steinmetz M.O., Maco B., Kammerer R.A., Ahn S.Y., et al. Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2. Journal of Biological Chemistry 2005, 280:20126-20131.
7. Procopio W.N., Pelavin P.I., Lee W.M., Yeilding N.M. Angiopoietin-1 and -2 coiled coil domains mediate distinct homo-oligomerization patterns, but fibrinogen-like domains mediate ligand activity. Journal of Biological Chemistry 1999, 274:30196-30201.
8. Davis S., Papadopoulos N., Aldrich T.H., Maisonpierre P.C., Huang T., Kovac L., et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Natural Structural Biology 2003, 10:38-44.
9. Xu Y., Yu Q. Angiopoietin-1, unlike angiopoietin-2, is incorporated into the extracellular matrix via its linker peptide region. Journal of Biological Chemistry 2001, 276:34990-34998.
10. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87:1171-1180.
11. Schubert S.Y., Benarroch A., Monter-Solans J., Edelman E.R. Primary monocytes regulate endothelial cell survival through secretion of angiopoietin-1 and activation of endothelial Tie2. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:870-875.
12. Fiedler U., Scharpfenecker M., Koidl S., Hegen A., Grunow V., Schmidt J.M., et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004, 103:4150-4156.
13. Zhang L., Yang N., Park J.W., Katsaros D., Fracchioli S., Cao G., et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Research 2003, 63:3403-3412.
14. Oh H., Takagi H., Suzuma K., Otani A., Matsumura M., Honda Y. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. Journal of Biological Chemistry 1999, 274:15732-15739.
15. Otani A., Takagi H., Oh H., Koyama S., Honda Y., Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells. Diabetes 2001, 50:867-875.
16. Wong A.L., Haroon Z.A., Werner S., Dewhirst M.W., Greenberg C.S., Peters K.G. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circulation Research 1997, 81:567-574.
17. Brkovic A., Pelletier M., Girard D., Sirois M.G. Angiopoietin chemotactic activities on neutrophils are regulated by PI-3K activation. Journal of Leukocyte Biology 2007, 81:1093-1101.
18. Kosacka J., Figiel M., Engele J., Hilbig H., Majewski M., Spanel-Borowski K. Angiopoietin-1 promotes neurite outgrowth from dorsal root ganglion cells positive for Tie-2 receptor. Cell and Tissue Research 2005, 320:11-19.
19. Nakayama T., Hatachi G., Wen C.Y., Yoshizaki A., Yamazumi K., Niino D., et al. Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: Immunohistochemical analysis and correlation with clinicopathological factors. World Journal of Gastroenterology 2005, 11:964-969.
20. Voskas D., Jones N., Van Slyke P., Sturk C., Chang W., Haninec A., et al. A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. American Journal of Pathology 2005, 166:843-855.
21. Uchida T., Nakashima M., Hirota Y., Miyazaki Y., Tsukazaki T., Shindo H. Immunohistochemical localisation of protein tyrosine kinase receptors Tie-1 and Tie-2 in synovial tissue of rheumatoid arthritis: correlation with angiogenesis and synovial proliferation. Annals of the Rheumatic Diseases 2000, 59:607-614.
22. Makinde T., Agrawal D.K. Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease. Journal of Cellular and Molecular Medicine 2008, 12:810-828.
23. Brindle N.P., Saharinen P., Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circulation Research 2006, 98:1014-1023.
24. Kwak H.J., Lee S.J., Lee Y.H., Ryu C.H., Koh K.N., Choi H.Y., et al. Angiopoietin-1 inhibits irradiation- and mannitol-induced apoptosis in endothelial cells. Circulation 2000, 101:2317-2324.
25. Dallabrida S.M., Ismail N., Oberle J.R., Himes B.E., Rupnick M.A. Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. Circulation Research 2005, 96:e8-e24.
26. Valable S., Bellail A., Lesné S., Liot G., Mackenzie E.T., Vivien D., et al. Angiopoietin-1-induced PI3-kinase activation prevents neuronal apoptosis. FASEB Journal 2003, 17:443-445.
27. Iurlaro M., Scatena M., Zhu W.H., Fogel E., Wieting S.L., Nicosia R.F. Rat aorta-derived mural precursor cells express the Tie2 receptor and respond directly to stimulation by angiopoietins. Journal of Cell Science 2003, 116:3635-3643.
28. Jones N., Chen S.H., Sturk C., Master Z., Tran J., Kerbel R.S., et al. A unique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function. Molecular and Cellular Biology 2003, 23:2658-2668.
29. Kim I., Kim H.G., Moon S.O., Chae S.W., So J.N., Koh K.N., et al. Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. Circulation Research 2000, 86:952-959.
30. Koblizek T.I., Weiss C., Yancopoulos G.D., Deutsch U., Risau W. Angiopoietin-1 induces sprouting angiogenesis in vitro. Current Biology 1998, 8:529-532.
31. Kim I., Moon S.O., Park S.K., Chae S.W., Koh G.Y. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circulation Research 2001, 89:477-479.
32. Gamble J.R., Drew J., Trezise L., Underwood A., Parsons M., Kasminkas L., et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circulation Research 2000, 87:603-607.
33. Hori S., Ohtsuki S., Hosoya K., Nakashima E., Terasaki T. A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. Journal of Neurochemistry 2004, 89:503-513.
34. Lee S.W., Kim W.J., Jun H.O., Choi Y.K., Kim K.W. Angiopoietin-1 reduces vascular endothelial growth factor-induced brain endothelial permeability via upregulation of ZO-2. International Journal of Molecular Medicine 2009, 23:279-284.
35. Seegar T.C., Eller B., Tzvetkova-Robev D., Kolev M.V., Henderson S.C., Nikolov D.B., et al. Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. Molecular Cell 2010, 37:643-655.
36. Hansen T.M., Singh H., Tahir T.A., Brindle N.P. Effects of angiopoietins-1 and -2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface. Cellular Signalling 2010, 22:527-532.
37. Kim H.Z., Jung K., Kim H.M., Cheng Y., Koh G.Y. A designed angiopoietin-2 variant, pentameric COMP-Ang2, strongly activates Tie2 receptor and stimulates angiogenesis. Biochimica et Biophysica Acta 2009, 1793:772-780.
38. Nyström P.O. The systemic inflammatory response syndrome: definitions and aetiology. Journal of Antimicrobial Chemotherapy 1998, 41(Suppl. A):1-7.
39. Huet O., Dupic L., Harrois A., Duranteau J. Oxidative stress and endothelial dysfunction during sepsis. Frontiers in Bioscience 2011, 16:1986-1995.
40. Worrall N.K., Chang K., LeJeune W.S., Misko T.P., Sullivan P.M., Ferguson T.B., et al. TNF-alpha causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and -independent mechanisms. American Journal of Physiology 1997, 273:H2565-H2574.
41. 2+ mobilization, barrier dysfunction, prostaglandin synthesis, and platelet-derived growth factor mRNA expression in cultured endothelium. Journal of Cellular Physiology 1993, 156:541-549.
42. Alves B.E., Montalvao S.A., Aranha F.J., Siegl T.F., Souza C.A., Lorand-Metze I., et al. Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia. BMC Infectious Diseases 2010, 10:143.
43. Mankhambo L.A., Banda D.L., IPD Study Group, Jeffers G., White S.A., Balmer P., et al. The role of angiogenic factors in predicting clinical outcome in severe bacterial infection in Malawian children. Critical Care 2010, 14:R91.
44. Kümpers P., Hafer C., David S., Hecker H., Lukasz A., Fliser D., et al. Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Medicine 2010, 36:462-470.
45. Kümpers P., van Meurs M., David S., Molema G., Bijzet J., Lukasz A., et al. Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis. Critical Care 2009, 13:R64.
46. Ebihara I., Hirayama K., Nagai K., Kakita T., Miyamoto Y., Nagai M., et al. Angiopoietin balance in septic shock patients treated by direct hemoperfusion with polymyxin b-immobilized fiber. Therapeutic Apheresis and Dialysis 2009, 13:520-527.
47. Siner J.M., Bhandari V., Engle K.M., Elias J.A., Siegel M.D. Elevated serum angiopoietin 2 levels are associated with increased mortality in sepsis. Shock 2009, 31:348-353.
48. van der Heijden M., Pickkers P., van Nieuw Amerongen G.P., van Hinsbergh V.W., Bouw M.P., van der Hoeven J.G., et al. Circulating angiopoietin-2 levels in the course of septic shock: relation with fluid balance, pulmonary dysfunction and mortality. Intensive Care Medicine 2009, 35:1567-1574.
49. Kümpers P., Lukasz A., David S., Horn R., Hafer C., Faulhaber-Walter R., et al. Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Critical Care 2008, 12:R147.
50. van der Heijden M., van Nieuw Amerongen G.P., Koolwijk P., van Hinsbergh V.W., Groeneveld A.B. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax 2008, 63:903-909.
51. Gallagher D.C., Parikh S.M., Balonov K., Miller A., Gautam S., Talmor D., et al. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock 2008, 29:656-661.
52. Lukasz A., Hellpap J., Horn R., Kielstein J.T., David S., Haller H., et al. Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays. Critical Care 2008, 12:R94.
53. Ganter M.T., Cohen M.J., Brohi K., Chesebro B.B., Staudenmayer K.L., Rahn P., et al. Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma?. Annals of Surgery 2008, 247:320-326.
54. Giuliano J.S., Lahni P.M., Harmon K., Wong H.R., Doughty L.A., Carcillo J.A., et al. Admission angiopoietin levels in children with septic shock. Shock 2007, 28:650-654.
55. Orfanos S.E., Kotanidou A., Glynos C., Athanasiou C., Tsigkos S., Dimopoulou I., et al. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Critical Care Medicine 2007, 35:199-206.
56. Parikh S.M., Mammoto T., Schultz A., Yuan H.T., Christiani D., Karumanchi S.A., et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Medicine 2006, 3:e46.
57. David S., Ghosh C.C., Kümpers P., Shushakova N., Van Slyke P., Khankin E.V., et al. Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality. American Journal of Physiology - Lung Cellular and Molecular Physiology 2011, 300:L851-L862.
58. David S., Park J.K., Meurs M., Zijlstra J.G., Koenecke C., Schrimpf C., et al. Acute administration of recombinant Angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis. Cytokine 2011, 55:251-259.
59. Kümpers P., Gueler F., David S., Van Slyke P., Dumont D.J., Park J.K., et al. The synthetic Tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Critical Care 2011, 15:R261.
60. Hwang J.A., Lee E.H., Lee S.D., Park J.B., Jeon B.H., Cho C.H. COMP-Ang1 ameliorates leukocyte adhesion and reinforces endothelial tight junctions during endotoxemia. Biochemical and Biophysical Research Communications 2009, 381:592-596.
61. Kim S.R., Lee K.S., Park S.J., Min K.H., Lee K.Y., Choe Y.H., et al. Angiopoietin-1 variant, COMP-Ang1 attenuates hydrogen peroxide-induced acute lung injury. Experimental and Molecular Medicine 2008, 40:320-331.
62. Huang Y.Q., Sauthoff H., Herscovici P., Pipiya T., Cheng J., Heitner S., et al. Angiopoietin-1 increases survival and reduces the development of lung edema induced by endotoxin administration in a murine model of acute lung injury. Critical Care Medicine 2008, 36:262-267.
63. Xu J., Qu J., Cao L., Sai Y., Chen C., He L., et al. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. Journal of Pathology 2008, 214:472-481.
64. Guo Q., Huang J.A., Jin J., Wang J., Fu J.H., Yang X.J. The protective effect of angiopoietin-1 on early acute lung injury induced by oleic acid in mice. Zhonghua Jie He He Hun Xi Za Zhi 2007, 30:926-931.
65. McCarter S.D., Mei S.H., Lai P.F., Zhang Q.W., Parker C.H., Suen R.S., et al. Cell-based angiopoietin-1 gene therapy for acute lung injury. American Journal of Respiratory and Critical Care Medicine 2007, 175:1014-1026.
66. Mei S.H., McCarter S.D., Deng Y., Parker C.H., Liles W.C., Stewart D.J. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Medicine 2007, 4:e269.
67. Witzenbichler B., Westermann D., Knueppel S., Schultheiss H.P., Tschope C. Protective role of angiopoietin-1 in endotoxic shock. Circulation 2005, 111:97-105.
68. Gutierrez-Ramos J.C., Bluethmann H. Molecules and mechanisms operating in septic shock: lessons from knockout mice. Immunology Today 1997, 18:329-334.
69. Childs E.W., Tharakan B., Byrge N., Tinsley J.H., Hunter F.A., Smythe W.R. Angiopoietin-1 inhibits intrinsic apoptotic signaling and vascular hyperpermeability following hemorrhagic shock. American Journal of Physiology - Heart and Circulatory Physiology 2008, 294:H2285-H2295.
70. Jung Y.J., Kim D.H., Lee A.S., Lee S., Kang K.P., Lee S.Y., et al. Peritubular capillary preservation with COMP-angiopoietin-1 decreases ischemia-reperfusion-induced acute kidney injury. American Journal of Physiology. Renal Physiology 2009, 297:F952-F960.
71. Schoch H.J., Fischer S., Marti H.H. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 2002, 125:2549-2557.
72. Nag S., Papneja T., Venugopalan R., Stewart D.J. Increased angiopoietin2 expression is associated with endothelial apoptosis and blood-brain barrier breakdown. Laboratory Investigation 2005, 85:1189-1198.
73. Zhang Z.G., Zhang L., Tsang W., Soltanian-Zadeh H., Morris D., Zhang R., et al. Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism 2002, 22:379-392.
74. Valable S., Montaner J., Bellail A., Berezowski V., Brillault J., Cecchelli R., et al. VEGF-induced BBB permeability is associated with an MMP-9 activity increase in cerebral ischemia: both effects decreased by Ang-1. Journal of Cerebral Blood Flow and Metabolism 2005, 25:1491-1504.
75. Li S.F., Meng Q.H., Yao W.C., Hu G.J., Li G.L., Li Z.J., et al. Recombinant AAV1 mediated vascular endothelial growth factor gene expression promotes angiogenesis and improves neural function: experiment with rats. Zhonghua Yi Xue Za Zhi 2009, 89:167-170.
76. Krupinski J., Kaluza J., Kumar P., Kumar S., Wang J.M. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 1994, 25:1794-1798.
77. Li S.F., Sun Y.B., Meng Q.H., Li S.R., Yao W.C., Hu G.J., et al. Recombinant adeno-associated virus serotype 1-vascular endothelial growth factor promotes neurogenesis and neuromigration in the subventricular zone and rescues neuronal function in ischemic rats. Neurosurgery 2009, 65:771-779. [discussion 779].
78. Wang Y.Q., Guo X., Qiu M.H., Feng X.Y., Sun F.Y. VEGF overexpression enhances striatal neurogenesis in brain of adult rat after a transient middle cerebral artery occlusion. Journal of Neuroscience Research 2007, 85:73-82.
79. Shin H.Y., Lee Y.J., Kim H.J., Park C.K., Kim J.H., Wang K.C., et al. Protective role of COMP-Ang1 in ischemic rat brain. Journal of Neuroscience Research 2010, 88:1052-1063.
80. Zhao Y., Li Z., Wang R., Wei J., Li G., Zhao H. Angiopoietin 1 counteracts vascular endothelial growth factor-induced blood-brain barrier permeability and alleviates ischemic injury in the early stages of transient focal cerebral ischemia in rats. Neurological Research 2010, 32:748-755.
81. Zhang Z.G., Zhang L., Croll S.D., Chopp M. Angiopoietin-1 reduces cerebral blood vessel leakage and ischemic lesion volume after focal cerebral embolic ischemia in mice. Neuroscience 2002, 113:683-687.
82. Ohab J.J., Fleming S., Blesch A., Carmichael S.T. A neurovascular niche for neurogenesis after stroke. Journal of Neuroscience 2006, 26:13007-13016.
83. Tsuji K., Aoki T., Tejima E., Arai K., Lee S.R., Atochin D.N., et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 2005, 36:1954-1959. [Epub 28 July 2005].
84. Wilkinson-Berka J.L., Miller A.G. Update on the treatment of diabetic retinopathy. Scientific World Journal 2008, 8:98-120.
85. Frank R.N. Diabetic retinopathy. New England Journal of Medicine 2004, 350:48-58. [Review].
86. Joussen A.M., Murata T., Tsujikawa A., Kirchhof B., Bursell S.E., Adamis A.P. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. American Journal of Pathology 2001, 158:147-152.
87. Klein R., Klein B.E., Moss S.E., Cruickshanks K.J. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XV. The long-term incidence of macular edema. Ophthalmology 1995, 102:7-16.
88. Lu M., Perez V.L., Ma N., Miyamoto K., Peng H.B., Liao J.K., et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Investigative Ophthalmology and Visual Science 1999, 40:1808-1812.
89. Qian H., Ripps H. Neurovascular interaction and the pathophysiology of diabetic retinopathy. Experimental Diabetes Research 2011, 69:3426.
90. Pfister F., Wang Y., Schreiter K., Vom Hagen F., Altvater K., Hoffmann S., et al. Retinal overexpression of angiopoietin-2 mimics diabetic retinopathy and enhances vascular damages in hyperglycemia. Acta Diabetologica 2010, 47:59-64.
91. Feng Y., Vom Hagen F., Pfister F., Djokic S., Hoffmann S., Back W., et al. Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thrombosis and Haemostasis 2007, 97:99-108.
92. Hammes H.P., Lin J., Wagner P., Feng Y., Vom Hagen F., Krzizok T., et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 2004, 53:1104-1110.
93. Rangasamy S., Srinivasan R., Maestas J., McGuire P.G., Das A. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Investigative Ophthalmology and Visual Science 2011, 52:3784-3791.
94. Joussen A.M., Poulaki V., Tsujikawa A., Qin W., Qaum T., Xu Q., et al. Suppression of diabetic retinopathy with angiopoietin-1. American Journal of Pathology 2002, 160:1683-1693.
95. Avery R.L., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., Giust M.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006, 113:363-372. e5.
96. Rees D.A., Alcolado J.C. Animal models of diabetes mellitus. Diabetic Medicine 2005, 22:359-370.
97. Chen J.X., Stinnett A. Disruption of Ang-1/Tie-2 signaling contributes to the impaired myocardial vascular maturation and angiogenesis in type II diabetic mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28:1606-1613.
98. Lubiatowski P., Gurunluoglu R., Goldman C.K., Skugor B., Carnevale K., Siemionow M. Gene therapy by adenovirus-mediated vascular endothelial growth factor and angiopoietin-1 promotes perfusion of muscle flaps. Plastic and Reconstructive Surgery 2002, 110:149-159.
99. Gurunluoglu R., Lubiatowski P., Goldman C.K., Carnevale K., Siemionow M. Enhancement of muscle flap hemodynamics by angiopoietin-1. Annals of Plastic Surgery 2002, 48:401-409.
100. Chae J.K., Kim I., Lim S.T., Chung M.J., Kim W.H., Kim H.G., et al. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arteriosclerosis, Thrombosis, and Vascular Biology 2000, 20:2573-2578.
101. Ritz E. Nephropathy in type 2 diabetes. Journal of Internal Medicine 1999, 245:111-126.
102. Gnudi L., Thomas S.M., Viberti G. Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. Journal of the American Society of Nephrology 2007, 18:2226-2232. [Epub 18 July 2007].
103. Karalliedde J., Gnudi L. Endothelial factors and diabetic nephropathy. Diabetes Care 2011, 34:S291-S296.
104. Lane J.T. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. American Journal of Physiology - Renal Physiology 2004, 286(March (3)):F442-F450. [Review. Erratum in: American Journal of Physiology - Renal Physiology 55, F1239].
105. Satchell S.C., Harper S.J., Tooke J.E., Kerjaschki D., Saleem M.A., Mathieson P.W. Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. Journal of the American Society of Nephrology 2002, 13:544-550.
106. Satchell S.C., Anderson K.L., Mathieson P.W. Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. Journal of the American Society of Nephrology 2004, 15:566-574.
107. Rasul S., Reiter M.H., Ilhan A., Lampichler K., Wagner L., Kautzky-Willer A. Circulating angiopoietin-2 and soluble Tie-2 in type 2 diabetes mellitus: a cross-sectional study. Cardiovascular Diabetology 2011, 10:55.
108. Lim H.S., Lip G.Y., Blann A.D. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 2005, 180:113-118.
109. Yao D., Taguchi T., Matsumura T., Pestell R., Edelstein D., Giardino I., et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. Journal of Biological Chemistry 2007, 282:31038-31045.
110. Tryggvason K., Patrakka J., Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. New England Journal of Medicine 2006, 354:1387-1401.
111. Davis B., Dei Cas A., Long D.A., White K.E., Hayward A., Ku C.H., et al. Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. Journal of the American Society of Nephrology 2007, 18:2320-2329.
112. Lee S., Kim W., Moon S.O., Sung M.J., Kim D.H., Kang K.P., et al. Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes. Nephrology, Dialysis, Transplantation 2007, 22:396-408.
113. Shibuya K., Kanasaki K., Isono M., Sato H., Omata M., Sugimoto T., et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes 2005, 54:838-845.
114. Elias J.A., Lee C.G., Zheng T., Ma B., Homer R.J., Zhu Z. New insights into the pathogenesis of asthma. Journal of Clinical Investigation 2003, 111:291-297.
115. Wilson J.W., Hii S. The importance of the airway microvasculature in asthma. Current Opinion in Allergy and Clinical Immunology 2006, 6:51-55.
116. Hoshino M., Nakamura Y., Hamid Q.A. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. Journal of Allergy and Clinical Immunology 2001, 107:1034-1038.
117. McDonald D.M. Angiogenesis and remodeling of airway vasculature in chronic inflammation. American Journal of Respiratory and Critical Care Medicine 2001, 164:S39-S45.
118. Van de Graaf E.A., Out T.A., Roos C.M., Jansen H.M. Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma, Effects of therapy with inhaled steroids. American Review of Respiratory Disease 1991, 143:362-368.
119. Kanazawa H., Nomura S., Asai K. Roles of angiopoietin-1 and angiopoietin-2 on airway microvascular permeability in asthmatic patients. Chest 2007, 131:1035-1041.
120. Simoes D.C., Vassilakopoulos T., Toumpanakis D., Petrochilou K., Roussos C., Papapetropoulos A. Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma. American Journal of Respiratory and Critical Care Medicine 2008, 177:1314-1321.
121. Lee K.S., Lee K.Y., Kim S.R., Park H.S., Park S.J., Min K.H., et al. Blockade of airway inflammation and hyper-responsiveness by an angiopoietin-1 variant, COMP-Ang1. Experimental and Molecular Medicine 2007, 39:733-745.
122. Byun S.J., Choi K.S., Park S.H., Cho N.W., Hyun Yoo C., Yun K.J., et al. Cartilage oligometric matrix protein-angiopoietin-1 promotes revascularization through increased survivin expression in dermal endothelial cells of skin grafts in mice. American Journal of Pathology 2007, 171:1682-1690.
123. Cho C.H., Sung H.K., Kim K.T., Cheon H.G., Oh G.T., Hong H.J., et al. COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood flow in a diabetic mouse model. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:4946-4951.
124. Cho C.H., Kim K.E., Byun J., Jang H.S., Kim D.K., Baluk P., et al. Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circulation Research 2005, 97:86-94.
125. Bhardwaj S., Roy H., Kärpänen T., He Y., Jauhiainen S., Hedman M., et al. Periadventitial angiopoietin-1 gene transfer induces angiogenesis in rabbit carotid arteries. Gene Therapy 2005, 12:388-394.
126. Tammela T., Saaristo A., Lohela M., Morisada T., Tornberg J., Norrmén C., et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005, 105:4642-4648.
127. Kim K.E., Cho C.H., Kim H.Z., Baluk P., McDonald D.M., Koh G.Y. In vivo actions of angiopoietins on quiescent and remodeling blood and lymphatic vessels in mouse airways and skin. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:564-570.
128. Van Slyke P., Alami J., Martin D., Kuliszewski M., Leong-Poi H., Sefton M.V., et al. Acceleration of diabetic wound healing by an angiopoietin peptide mimetic. Tissue Engineering Part A 2008, 15:1269-1280.
129. Bitto A., Minutoli L., Galeano M.R., Altavilla D., Polito F., Fiumara T., et al. Angiopoietin-1 gene transfer improves impaired wound healing in genetically diabetic mice without increasing VEGF expression. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:564-570.
130. Jung H., Gurunluoglu R., Scharpf J., Siemionow M. Adenovirus-mediated angiopoietin-1 gene therapy enhances skin flap survival. Microsurgery 2003, 23:374-380.
131. Shyu K.G., Manor O., Magner M., Yancopoulos G.D., Isner J.M. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 1998, 98:2081-2087.
132. Chen F., Tan Z., Dong C.Y., Chen X., Guo S.F. Adeno-associated virus vectors simultaneously encoding VEGF and angiopoietin-1 enhances neovascularization in ischemic rabbit hind-limbs. Acta Pharmacologica Sinica 2007, 28:493-502.
133. Shyu K.G., Chang H., Isner J.M. Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sciences 2003, 73:563-579.
134. Yamauchi A., Ito Y., Morikawa M., Kobune M., Huang J., Sasaki K., et al. Pre-administration of angiopoietin-1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model. Journal of General Microbiology 2003, 5:994-1004.
135. Su H., Takagawa J., Huang Y., Arakawa-Hoyt J., Pons J., Grossman W., et al. Additive effect of AAV-mediated angiopoietin-1 and VEGF expression on the therapy of infarcted heart. International Journal of Cardiology 2009, 133:191-197.
136. Takahashi K., Ito Y., Morikawa M., Kobune M., Huang J., Tsukamoto M., et al. Adenoviral-delivered angiopoietin-1 reduces the infarction and attenuates the progression of cardiac dysfunction in the rat model of acute myocardial infarction. Molecular Therapy 2003, 8:584-592.
137. Liu X., Chen Y., Zhang F., Chen L., Ha T., Gao X., et al. Synergistically therapeutic effects of VEGF165 and angiopoietin-1 on ischemic rat myocardium. Scandinavian Cardiovascular Journal 2007, 41:95-101.
138. Siddiqui A.J., Blomberg P., Wärdell E., Hellgren I., Eskandarpour M., Islam K.B., et al. Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium. Biochemical and Biophysical Research Communications 2003, 310:1002-1009.
139. Zhou L., Ma W., Yang Z., Zhang F., Lu L., Ding Z., et al. VEGF165 and angiopoietin-1 decreased myocardium infarct size through phosphatidylinositol-3 kinase and Bcl-2 pathways. Gene Therapy 2005, 12:196-202.
140. Tao Z., Chen B., Tan X., Zhao Y., Wang L., Zhu T., et al. Coexpression of VEGF and angiopoietin-1 promotes angiogenesis and cardiomyocyte proliferation reduces apoptosis in porcine myocardial infarction (MI) heart. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:2064-2069.
141. Holash J., Wiegand S.J., Yancopoulos G.D. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999, 18:5356-5362.
142. Coffelt S.B., Tal A.O., Scholz A., De Palma M., Patel S., Urbich C., et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Research 2010, 70:5270-5280.
143. Leow C.C., Coffman K., Inigo I., Breen S., Czapiga M., Soukharev S., et al. MEDI3617, a human anti-Angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. International Journal of Oncology 2012, 40:1321-1330.
144. Brown J.L., Cao Z.A., Pinzon-Ortiz M., Kendrew J., Reimer C., Wen S., et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Molecular Cancer Therapeutics 2010, 9:145-156.
145. Sarraf-Yazdi S., Mi J., Moeller B.J., Niu X., White R.R., Kontos C.D., et al. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. Journal of Surgical Research 2008, 146:16-23.
146. Morrissey C., Dowell A., Koreckij T.D., Nguyen H., Lakely B., Fanslow W.C., et al. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate 2010, 70:1799-1808.
147. Falcón B.L., Hashizume H., Koumoutsakos P., Chou J., Bready J.V., Coxon A., et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. American Journal of Pathology 2009, 175:2159-2170.
148. Coxon A., Bready J., Min H., Kaufman S., Leal J., Yu D., et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Molecular Cancer Therapeutics 2010, 9:2641-2651.
149. Hashizume H., Falcón B.L., Kuroda T., Baluk P., Coxon A., Yu D., et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Research 2010, 70:2213-2223.
150. Oliner J., Min H., Leal J., Yu D., Rao S., You E., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.
151. Huang H., Lai J.Y., Do J., Liu D., Li L., Del Rosario J., et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clinical Cancer Research 2011, 17:1001-1011.
152. Holopainen T., Saharinen P., D'Amico G., Lampinen A., Eklund L., Sormunen R., et al. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. Journal of the National Cancer Institute 2012, 104:461-475.
153. Mazzieri R., Pucci F., Moi D., Zonari E., Ranghetti A., Berti A., et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011, 19:512-526.
154. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
155. Huang J., Bae J.O., Tsai J.P., Kadenhe-Chiweshe A., Papa J., Lee A., et al. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. International Journal of Oncology 2009, 34:79-87.
156. Karlan B.Y., Oza A.M., Richardson G.E., Provencher D.M., Hansen V.L., Buck M., et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. Journal of Clinical Oncology 2012, 30:362-371.
157. Cho C.H., Kammerer R.A., Lee H.J., Steinmetz M.O., Ryu Y.S., Lee S.H., et al. COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:5547-5552.
158. Donsante A., Miller D.G., Li Y., Vogler C., Brunt E.M., Russell D.W., et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007, 317:477.
159. McTiernan C.F., Mathier M.A., Zhu X., Xiao X., Klein E., Swan C.H., et al. Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts. Gene Therapy 2007, 14(December (23)):1613-1622.
160. Phillips J.E., Gersbach C.A., García A.J. Virus-based gene therapy strategies for bone regeneration. Biomaterials 2007, 28:211-229.
161. Paul A., Prakash S. Baculovirus reveals a new pH-dependent direct cell-fusion pathway for cell entry and transgene delivery. Future Virology 2010, 5:533-537.
162. Chuang C.K., Wong T.H., Hwang S.M., Chang Y.H., Chen G.Y., Chiu Y.C., et al. Baculovirus transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantation. Molecular Therapy 2009, 17:889-896.
163. Paul A., Binsalamah Z.M., Khan A.A., Abbasia S., Elias C.B., Shum-Tim D., et al. A nanobiohybrid complex of recombinant baculovirus and Tat/DNA nanoparticles for delivery of Ang-1 transgene in myocardial infarction therapy. Biomaterials 2011, 32:8304-8318.
164. Phelps E.A., Landázuri N., Thulé P.M., Taylor W.R., García A.J. Bioartificial matrices for therapeutic vascularization. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:3323-3328.
165. Silva E.A., Mooney D.J. Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. Journal of Thrombosis and Haemostasis 2007, 5:590-598.
166. Sun Q., Chen R.R., Shen Y., Mooney D.J., Rajagopalan S., Grossman P.M. Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharmaceutical Research 2005, 22:1110-1116.
167. Chiu L.L., Radisic M. Scaffolds with covalently immobilized VEGF and Angiopoietin-1 for vascularization of engineered tissues. Biomaterials 2010, 31:226-241.
168. Saif J., Schwarz T.M., Chau D.Y., Henstock J., Sami P., Leicht S.F., et al. Combination of injectable multiple growth factor-releasing scaffolds and cell therapy as an advanced modality to enhance tissue neovascularization. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30:1897-1904.
169. Lu H., Xu X., Zhang M., Cao R., Bråkenhielm E., Li C., et al. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:12140-12145.
170. Richardson T.P., Peters M.C., Ennett A.B., Mooney D.J. Polymeric system for dual growth factor delivery. Nature Biotechnology 2001, 19:1029-1034.
171. Khan A.A., Paul A., Abbasi S., Prakash S. Mitotic and antiapoptotic effects of nanoparticles coencapsulating human VEGF and human angiopoietin-1 on vascular endothelial cells. International Journal of Nanomedicine 2011, 6:1069-1081.
172. Golub J.S., Kim Y.T., Duvall C.L., Bellamkonda R.V., Gupta D., Lin A.S., et al. Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. American Journal of Physiology - Heart and Circulatory Physiology 2010, 298:H1959-H1965.
173. Castellani P., Viale G., Dorcaratto A., Nicolo G., Kaczmarek J., Querze G., et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. International Journal of Cancer 1994, 59:612-618.
174. Ventura E., Balza E., Borsi L., Tutolo G., Carnemolla B., Castellani P., et al. Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report. BMC Biotechnology 2011, 11:104.
175. Kaspar M., Trachsel E., Neri D. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Research 2007, 67:4940-4948.
176. Carnemolla B., Borsi L., Balza E., Castellani P., Meazza R., Berndt A., et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002, 99:1659-1665.
177. Cho C.H., Kammerer R.A., Lee H.J., Yasunaga K., Kim K.T., Choi H.H., et al. Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:5553-5558.
178. Kim D.H., Jung Y.J., Lee A.S., Lee S., Kang K.P., Lee T.H., et al. COMP-angiopoietin-1 decreases lipopolysaccharide-induced acute kidney injury. Kidney International 2009, 76:1180-1191.
179. Tournaire R., Simon M.P., le Noble F., Eichmann A., England P., Pouysségur J. A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Reports 2004, 5:262-267.
180. Takagi H., Koyama S., Seike H., Oh H., Otani A., Matsumura M., et al. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Investigative Ophthalmology and Visual Science 2003, 44:393-402.
181. Chen D., Brahimi F., Angell Y., Li Y.C., Moscowicz J., Saragovi H.U., et al. Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals. ACS Chemical Biology 2009, 4:769-781.
182. Zaccaro M.C., Lee H.B., Pattarawarapan M., Xia Z., Caron A., L'Heureux P.J., et al. Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. Chemistry and Biology 2005, 12:1015-1028.
183. Stein E., Lane A.A., Cerretti D.P., Schoecklmann H.O., Schroff A.D., Van Etten R.L., et al. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes and Development 1998, 12:667-678.
184. Zhou J., Zhang Z.X., Zhao H., Zhu D.M., Zhang Y., Li D.C. Anti-angiogenesis by lentivirus-mediated small interfering RNA silencing of angiopoietin-2 gene in pancreatic carcinoma. Technology in Cancer Research and Treatment 2011, 10:361-369.
185. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
186. White R.R., Shan S., Rusconi C.P., Shetty G., Dewhirst M.W., Kontos C.D., et al. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:5028-5033.
187. Rennel E.S., Regula J.T., Harper S.J., Thomas M., Klein C., Bates D.O. A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis. Microcirculation 2011, 18:598-607.
188. Holopainen T., Huang H., Chen C., Kim K.E., Zhang L., Zhou F., et al. Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment. Cancer Research 2009, 69:4656-4664.
189. Liu X.H., Bai C.G., Yuan Y., Gong D.J., Huang S.D. Angiopoietin-1 targeted RNA interference suppresses angiogenesis and tumor growth of esophageal cancer. World Journal of Gastroenterology 2008, 14:1575-1581.
190. Wang J., Wu K.C., Zhang D.X., Fan D.M. Antisense angiopoietin-1 inhibits tumorigenesis and angiogenesis of gastric cancer. World Journal of Gastroenterology 2006, 12:2450-2454.
191. Shim W.S., Teh M., Bapna A., Kim I., Koh G.Y., Mack P.O., et al. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Experimental Cell Research 2002, 279:299-309.
192. Shim W.S., Teh M., Mack P.O., Ge R. Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice. International Journal of Cancer 2001, 94:6-15.
193. Hashiramoto A., Sakai C., Yoshida K., Tsumiyama K., Miura Y., Shiozawa K., et al. Angiopoietin 1 directly induces destruction of the rheumatoid joint by cooperative, but independent, signaling via ERK/MAPK and phosphatidylinositol 3-kinase/Akt. Arthritis and Rheumatism 2007, 56:2170-2179.
194. Long D.A., Price K.L., Ioffe E., Gannon C.M., Gnudi L., White K.E., et al. Angiopoietin-1 therapy enhances fibrosis and inflammation following folic acid-induced acute renal injury. Kidney International 2008, 74:300-309.
195. Dewachter L., Adnot S., Fadel E., Humbert M., Maitre B., Barlier-Mur A.M., et al. Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2006, 174:1025-1033.
196. Kugathasan L., Ray J.B., Deng Y., Rezaei E., Dumont D.J., Stewart D.J. The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice. Journal of Experimental Medicine 2009, 206:2221-2234.
197. Zhao Y.D., Campbell A.I., Robb M., Ng D., Stewart D.J. Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circulation Research 2003, 92:984-991.
198. Wolfram J.A., Diaconu D., Hatala D.A., Rastegar J., Knutsen D.A., Lowther A., et al. Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis. American Journal of Pathology 2009, 174:1443-1458.